The Somnomed share price dipped more than 2% lower today. We look at the company’s current position and consider the impacts of COVID-19 on its share price.
The post What’s behind the sleepy Somnomed (ASX:SOM) share price? appeared first on The Motley Fool Australia. –
The Somnomed Limited (ASX: SOM) share price closed 2.3% lower today at $2.12.
While the SomnoMed share price has bounced back 67.5% over the past half year, it still remains more than 11% down on this time last year. We take a closer look at what’s been impacting the healthcare equipment company’s share price.
2020 financial year highlights
The Somnomed AGM presentation from November 2020 draws attention to strong growth in the US and new sales leadership heading up Canada. New key appointments were also announced in Sydney.
Somnomed continued to promote the company’s continuous open airway therapy (COAT) technology as a best-in-class treatment for sleep apnea. The company did not offer FY 2021 guidance in its latest report, due to uncertainties created by COVID-19.
Comparing FY19 to FY20, revenue was down 3% and earnings before interest, tax, depreciation and amortisation (EBITDA) took a 5% hit.
Commenting on the company’s previous 12-month performance, CEO Neil Verdal-Austin said, “The past 12-months have been a mixed bag of, on the one side an incredible overall performance to March but on the other side, a dramatic and almost reverse of those fortunes in Q4 due to COVID-19.”
Why did COVID-19 serve such a harsh blow to the Somnomed share price?
Unfortunately, there are a few middle-men between Somnomed and its customer base. A doctor needs to diagnose a condition, a dentist is then required to fit the COAT device.
During times of lockdowns caused by a global pandemic, people simply can’t accommodate these types of services. That means sales go down.
From a $2.95 close on 20 February 2020 to 91 cents on 06 April 2020, it’s very clear that the coronavirus had a fierce impact on the company’s shares.
However, in more positive news, as we move into 2021 Morgans has retained a positive recommendation for Somnomed shares and has increased the target price to $2.55, up from $2.02.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
- The Energy Technologies (ASX:EGY) share price has charged 9% higher. Here’s why.
- Why the Cue Energy (ASX:CUE) share price is soaring 9% today
- Why the Northern Star and Saracen Mineral merger is getting closer
- 2 fantastic ASX shares to buy and hold until 2031
- Joe Biden unveils massive US$1.9 trillion coronavirus stimulus package
Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.